Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03913234|
Recruitment Status : Recruiting
First Posted : April 12, 2019
Last Update Posted : October 27, 2020
Survival benefit and quality of life are two key elements that should be kept in mind in the treatment of metastatic breast cancer. In this regards, endocrine therapy (ET) is strongly recommended in hormone receptor (HR) positive patients unless there is visceral crisis even though there is no concrete evidence that it is better than chemotherapy in terms of survival.
HER2 positive breast cancer is a subtype of breast cancer that showed the greatest improvement in terms of survival during the last decade due to trastuzumab based therapy. Recently, taxane and HER2 directed doublet including trastuzumab and pertuzumab (THP) is considered as standard of therapy based upon randomized phase 3 clinical trial (CLEOTATRA).
HER2 positive breast cancer can be divided into HER2 enriched subgroup (HR-HER2+) and luminal B subgroup (HR+HER2+) in biologic viewpoint because they are distinctly different subgroups in gene expression analysis. Accordingly, we are currently treating biologically different subtypes in a same way, which is CTx and anti-HER2 combination therapy (THP).
Luminal HER2+ subgroup has actually been tested with endocrine therapy (ET) and anti-HER2 therapy showed better PFS than ET alone (TAnDEM trial and trial comparing lapatinib plus letrozole versus letrozole alone) , confirming existence of cross talk between ER and HER2 pathways in clinical setting. However, the combination regimen between ET and anti-HER2 therapy is not widely used in current practice in ER+HER2+ MBC patients because PFS seemed to be relatively shorter compared with chemotherapy based combination with anti-HER2 therapy even though several guidelines recommend it to be used as an initial treatment unless there is visceral crisis as they recommended ET alone first in ER+HER2- MBC (NCCN 2018).
Recently, various CDK4/6 inhibitors including palbociclib, abemaciclib, and ribociclib were approved by FDA based on the clinical trial results demonstrating prolonged PFS over ET alone when it was combined with ET in ER+ advanced breast cancer . In PALOMA 2 biomarker study, it was beneficial regardless of ER and Ki67 expression status.
Reflecting quite durable PFS prolongation (10 month in PALOMA2) shown in ER+ disease (luminal A and luminal B subtype except HR+HER2+ patients) with CDK4/6 inhibitor on top of ET, the hypothesis of this trial is whether CDK4/6 inhibitor could prolong survival in luminal HER2 breast cancer as it did in ER+HER2-patients. In preclinical study, palbociclib showed activity in not only ER+ cell lines but also HER2 positive cell lines . Also, in phase Ib trial, a CDK4/6 inhibitor from Lilly, abemaciclib showed acceptable toxicity with endocrine therapy or trastuzumab with response rate of around 20%.
Hence, as of today, it could be justified and warranted to conduct a prospective trial of ribocicib+letrozole+trastuzumab in order to take a look at its efficacy and toxicity in HR+HER2 + advanced breast cancer.
|Condition or disease||Intervention/treatment||Phase|
|HER2-positive Breast Cancer Postmenopausal Metastatic Breast Cancer||Drug: Ribociclib, Trastuzumab, Letrozole||Phase 1 Phase 2|
This trial is performed in a multicenter, single-group, and phases IB and II clinical trial.
This is a single-group clinical trial of the effects of ribociclib, letrozole and trastuzumab in postmenopausal women with HR+, HER2+ advanced breast cancer. This trial consists of two parts. The first part is a phase IB study of increasing the dose of ribociclib from 200mg to 600mg in combination with letrozole 2.5mg and trastuzumab (8mg/kg followed by 6mg/kg every 3 weeks). In phase IB study, three to six patients will be enrolled for each dose group.
When the IB phase ends, patient enrollment will be discontinued for intermediate safety analysis, and after DLT analysis will determine recommended phase II phase II part will be started. The recommended phase II dose of ribocicib determined in phase IB part with ribociclib and trastuzumab (8mg/kg followed by 6mg/kg every 3 weeks) will be administered. Treatment is discontinued in the following cases.
- Progression of disease
- Uncontrolled toxicity
- Patient's death
- Withdrawal of consent In phase II part, 61 patients will be enrolled and the first 20 patients will be analyzed for run-in phase to confirm the safety of the therapy.
Regardless of treatment cycle, the disease will be evaluated in the same manner as the method used at the time of registration at intervals of 8 weeks for the first 18 months and at intervals of 12 weeks after that. If the progress of the disease is clinically suspected, additional tests can be performed
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||95 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients|
|Actual Study Start Date :||June 10, 2019|
|Estimated Primary Completion Date :||June 30, 2021|
|Estimated Study Completion Date :||December 30, 2021|
Experimental: Combination of Letrozole, Trastuzumab with Ribociclib
Phase IB (dose escalation of ribociclib with fixed dose of letrozole and Ribociclib) Phase II (ribociclib of RPIID with fixed dose of letrozole and ribociclib)
Drug: Ribociclib, Trastuzumab, Letrozole
Phase IB: letrozole 2.5mg (fixed dose), trastuzumab (8mg/kg loading followed by 6mg/kg q 3weeks, fixed dose) plus ribociclib (dose escalation from 200mg to 600mg) to identify recommended phase iI dose (RPIID) Phase II: letrozole, trastuzumab (same as phase IB) plus ribocicilb RPIID
- Progression free survival [ Time Frame: 1 year ]Progression free survival is defined as the time from the start of investigational drug to disease progression or patient's death whichever occurred first
- Overall survival [ Time Frame: 1 year ]Overall survival is the time from the start of investigational drug to patient's death.
- Response rate [ Time Frame: 1 year ]Response rate is defined as the response to the drug according to RECIST v1.1 criteria.
- Quality of life [ Time Frame: 1 year ]Overall survival is the time from the start of investigational drug to patient's death Response rate is defined as the response to the drug according to RECIST v1.1 criteria Quality of life will be measured using EORTC-QLQ C30 questionaire. (Purpose of EORTC-QLQ C30 is to measure the quality of life of the subjects who participated in the clinical study. It consists of 30 questions and each question will be answered by 4 scale answers "Not at all", "A little", "Quite a bit", and "Very much".)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03913234
|Contact: Joo Hyuk Sohn, Md, PhDemail@example.com|
|Korea, Republic of|
|Yonsei Cancer Center at Yonsei University Health System||Recruiting|
|Seoul, Korea, Republic of, 03722|
|Contact: Joo Hyuk Sohn, MD, PhD 82-2-2228-8135 firstname.lastname@example.org|